Though Teva says it isn't a surprise to the plant's 236 employees, the drugmaker plans to shutter its Pomona, NY manufacturing site.
The Pomona plant focuses on the manufacture of niacin for cholesterol treatment and also hosts research and development operations.
Terminations have already begun and will continue until the plant's closing date in February 2017.
The plant's closing will allow Teva to consolidate its R&D operations at a site in Elizabeth, NJ, following the acquisition of Actavis Generics, which was completed in early August. With the loss of patent on its top-selling multiple sclerosis treatment, Copaxone, Teva has been looking to cut plants and headcount to compensate for financial struggles.
Read the USA Today article